OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients

NCT03698227 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Lack of efficacy on olaratumab

Conditions

Advanced Soft Tissue Sarcoma

Interventions

DRUG: Olaratumab
DRUG: Dexrazoxane
DRUG: Doxorubicin

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest